BioSpace News Archive

ALLO-501 with ALLO-647 Lymphodepletion was Well Tolerated with No Dose-Limiting Toxicities, Graft-vs-Host Disease or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) In the Ongoing Study, 22 Patients were Evaluable for Safety and 19 Patients Were Evaluable for Efficacy with at Least One Tumor Assessment as of Data Cutoff Seven Complete Responses (CR) and Five Partial Responses (PR) were Observed for an Overall Response Rate (ORR) of 63% and CR Rate of 37% Higher Response Rates

Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial, which evaluated XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC).

Gracell Biotechnologies Co., Ltd. (“Gracell”), a clinical-stage immune cell and gene therapy company, today announced that two presentations were accepted at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

- New data and society guidelines support value of Oncotype DX Breast Recurrence Score® test in guiding neoadjuvant treatment decisions for newly diagnosed patients - Mayo Clinic collaboration yielding new data and insights on some of the deadliest cancers

The combination of DNA sequencing and whole transcriptome sequencing provides critical insights that can guide treatment decisions across a range of cancers

Presentations outline how BluePrint® genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients’ benefit FLEX registry reinforces the clinical and real-world utility of MammaPrint® and BluePrint to improve stratification of breast cancer patients [29-May-2020] IRVINE, Calif. and AMSTERDAM , May 29,

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive d

-- Registrational data in RET fusion-positive NSCLC show 61% ORR in patients previously treated with platinum-based chemotherapy and 73% ORR in treatment-naïve patients -- -- 12% complete response rate in patients with treatment-naïve RET fusion-positive NSCLC -- -- Median DOR not reached across lines of therapy in RET fusion-positive NSCLC, with 6-month DOR of 86% -- -- NDA accepted by FDA and MAA validated by EMA for pralsetinib in RET fusion-positive NSCLC --

Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up CRs are 20%, nearly tripling with two additional years of follow-up Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced new, longer-term data for PD-1 inhibitor Libtayo ® (cem